All In MedTech

FDA Clearance Tracker · P970004-S073

INTERSTIM THERAPY FOR URINARY CONTROL

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 26, 2009 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 26, 2009

Approved

Time to decision

181 days

Received Apr 28, 2009. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P970004-S073
Device name
INTERSTIM THERAPY FOR URINARY CONTROL
Applicant location
Minneapolis, MN
Received
Apr 28, 2009
Decided
Oct 26, 2009
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P970004

Device type

Device class
Class III
Regulation
21 CFR 876.5270

Every decision under product code EZW

FDA's approval statement

As written in FDA's record.

APPROVAL FOR CHANGES TO THE EXISTING MODEL 3093 AND MODEL 3889 INTERSTIM TINED LEADS, THE ADDITION OF AN ALTERNATIVE STYLET DESIGN TO BE INCLUDED IN THE MODEL 3093 AND MODEL 3889 LEADS KITS, AND A MINOR REVISION TO THE LABELING TO UPDATE THE LIST OF PACKAGE CONTENTS FOR THE MODEL 3093 AND MODEL 3889 LEADS KITS.

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.